Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reviewed the publication trends and key findings on alternative therapies for androgenetic alopecia, highlighting the increasing research interest in dutasteride and nontopical minoxidil, while noting a lack of high-quality trials for nontopical minoxidil formulations.

The study concluded that dutasteride 0.5 mg daily for 24 weeks was the most effective monotherapy for increasing hair density in men with androgenetic alopecia, compared to other interventions.

In this research review, the authors note that while topical minoxidil and oral finasteride are FDA-approved treatments for male androgenetic alopecia, some patients experience inadequate responses or side effects, prompting exploration of alternative therapies like newer 5-α reductase inhibitors and androgen receptor antagonists.

This source suggests that oral minoxidil could be a safe and effective treatment option for both female and male androgenetic alopecia, although it is currently used off-label.

This study found that men who smoke are more likely to develop androgenetic alopecia and experience disease progression compared to non-smokers.

This study compared the effectiveness of topical finasteride, oral finasteride, and topical minoxidil over 12 months in postmenopausal women with androgenetic alopecia, exploring their therapeutic effects on this population. Results are not reported in the abstract.

This systematic review concluded that mesotherapy shows potential for improving hair growth outcomes, yet lacks standardized regimens and requires further large-scale trials to establish its efficacy and safe use.

This research highlights that while minoxidil and 5-alpha reductase inhibitors are commonly used for treating pattern hair loss, there is limited evidence supporting their relative effectiveness in women compared to men.

This review discusses the potential of low-dose oral minoxidil as a safe and effective treatment for certain hair disorders, including alopecia, but reports no new clinical results.

This study concluded that combining 5% minoxidil with microneedling was more effective in improving hair density at 6 months for adults with pattern hair loss compared to other treatments analyzed.

Results are not reported for this review, which aimed to gather evidence on the effect of platelet-rich plasma monotherapy for androgenetic alopecia in men and women.

This report presents a rare case where a patient with chronic urticaria developed alopecia areata during azathioprine therapy, accompanied by bone marrow suppression; these effects resolved after stopping the medication, suggesting a possible link between azathioprine and autoimmune activation despite its intended immunosuppressive use.

This study found that the combination of minoxidil, microneedling, and platelet-rich plasma was more effective for androgenetic alopecia than minoxidil alone, although adverse effects were noted.

This study found that serum prolactin levels were significantly higher in patients with psoriasis, alopecia areata, and vitiligo compared to healthy controls, and prolactin levels were also correlated with disease severity in psoriasis and alopecia areata patients.

This study observed that in Assam Hill Goats, the primary hair follicles had larger diameters and more structural associations compared to secondary follicles, especially in ruminant-age groups.

This study reported that while topical minoxidil exhibits hair regrowth in androgenetic alopecia, oral minoxidil 5 mg/day was more effective than topical forms after six months, with low doses also potentially effective for women and other hair loss types.

This meta-analysis reported that 0.5 mg/d of dutasteride significantly increased total hair count at 24 weeks compared to finasteride and minoxidil in men with androgenetic alopecia.

This meta-analysis reported that finasteride 1 mg/day significantly increased hair count in male androgenetic alopecia compared to placebo, but highlighted persistent sexual side effects and associated depression risk.

This review found that topical finasteride has similar efficacy to oral finasteride in treating male and female pattern hair loss, with fewer systemic side effects, mainly causing localized scalp reactions like irritation and erythema.

Natural products like saw palmetto, caffeine, melatonin, marine extracts, rosemary oil, procyanidin, pumpkin seed oil, and cannabidiol oil could potentially treat male hair loss.

This study found that for people with androgenetic alopecia, increasing the dosage of low-dose oral minoxidil is associated with improvements in hair diameter and density, but also raises the risk of hypertrichosis and cardiovascular adverse events.

This study found that oral baricitinib was more effective than methotrexate in treating severe alopecia areata, with significant improvements in SALT scores over six months.

In this study, the authors reported that oral dutasteride at 0.5 mg/day showed a probable greater efficacy in treating male androgenetic alopecia compared to finasteride and minoxidil, but it may cause sexual dysfunction and neuropsychiatric side effects.

Results are not reported in this abstract, but it outlines the objective to evaluate the efficacy of microneedling, alone and in combination with other treatments, for pattern hair loss through a systematic review and meta-analysis.

This protocol outlines a planned systematic review on the effectiveness and safety of non-conventional treatments for male androgenetic alopecia, reporting no new results.

In this chapter, the authors emphasize the significant therapeutic roles attributed to Allium tuberosum due to its rich phytochemicals, detailing potential benefits against various conditions like diabetes, cancer, and liver dysfunction, as well as its applications in anticoagulation, muscle cell proliferation, and sensory perception mediation.

This study suggests that elevated levels of IL-17A and IL-23 in alopecia areata may play roles in disease severity and activity, providing insights into potential therapeutic targets.

In this randomized controlled trial, researchers found that after six months of treatment, oral baricitinib was significantly more effective than methotrexate for improving hair regrowth in patients with severe alopecia areata, as measured by the Severity of Alopecia Tool score.

This study found that a combination of minoxidil, microneedling, and PRP was significantly more effective than minoxidil alone in managing androgenetic alopecia over six months.